LOCALLY ADVANCED RECTAL CANCER (LARC)
Clinical trials for LOCALLY ADVANCED RECTAL CANCER (LARC) explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED RECTAL CANCER (LARC) trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED RECTAL CANCER (LARC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo takes on tough rectal cancer
Disease control OngoingThis phase 2 trial is testing whether adding two drugs—a PCSK9 inhibitor and a PD-1 inhibitor—to standard chemoradiotherapy can help shrink tumors in patients with locally advanced rectal cancer that has a specific genetic profile (pMMR/MSS). The study involves 30 participants an…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy aims to skip radiation for rectal cancer patients
Disease control OngoingThis study tests a new approach for people with locally advanced rectal cancer that has a common genetic profile (MSS/pMMR). Instead of standard radiation before surgery, participants receive a combination of chemotherapy (mFOLFOX6) and an immunotherapy drug (PD-1 antibody). The …
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: NA • Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC